Angle PLC Announces Issue of Equity

Rhea-AI Summary

ANGLE plc (OTCQX:ANPCY) has issued 70,000 new ordinary shares following the exercise of employee options. These shares, valued at £0.10 each, will rank pari passu with existing shares and are set to be admitted to AIM on November 18, 2021. This raises the total number of ordinary shares to 235,043,717. ANGLE specializes in liquid biopsy technologies, focusing on cancer diagnostics, and aims for FDA clearance for its Parsortix system, which has shown promising results in clinical trials for metastatic breast cancer and ovarian cancer.

Positive

• Issued 70,000 new ordinary shares, enhancing liquidity and potential market cap.
• Total shares now at 235,043,717, increasing visibility in the market.
• Strong background in liquid biopsy technologies, with proven clinical study results having an AUC-ROC of 95.1% in ovarian cancer testing.

Negative

• Pending FDA clearance for the Parsortix system, which could delay market competitiveness.

Issue of Equity

Exercise of Options and Total Voting Rights

GUILDFORD, SURREY / ACCESSWIRE / November 12, 2021 / ANGLE plc (AIM: AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 70,000 new ordinary shares of £0.10 each ("New Ordinary Shares") in the Company. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares in the Company.

An application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted. to trading on AIM (" Admission ") and it is expected that Admission will become effective, and trading will commence at 8.00 a.m. on 18 November 2021. Following Admission, the total number of Ordinary Shares in issue, and therefore the total number of voting rights, will be 235,043,717.

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc www.angleplc.com

ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

ANGLE's cell separation technology is called the Parsortix ^® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all types of CTCs as well as CTC clusters in a viable form (alive). CTCs enable the complete picture of a cancer to be seen; as being an intact cell they allow DNA, RNA and protein analysis and may provide comparable analysis to a tissue biopsy. Because CTC analysis is a non-invasive process, unlike tissue biopsy, it can be repeated as often as needed. This is important because cancer develops and changes over time and there is a clear medical need for up-to-date information on the status of a patient's tumor. In addition, the live CTCs harvested by the Parsortix system can be cultured, which offers the potential for testing tumor response to drugs outside the patient.

The Parsortix technology is the subject of 26 granted patents in Europe, the United States, China, Australia, Canada, India, Japan and Mexico with three extensive families of patents are being progressed worldwide.

The Parsortix system has a CE Mark in Europe for the indicated use and, in the United States, a De Novo Submission has been made to FDA for the Parsortix ^® PC1 system seeking FDA clearance with Class II Classification for use with metastatic breast cancer patients. FDA clearance is seen as the global standard. ANGLE is seeking to be the first ever FDA cleared system for harvesting CTCs for subsequent analysis.

ANGLE has also completed two separate 200 subject clinical studies under a program designed to develop an ovarian cancer pelvic mass triage test, with the results showing best in class accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has undergone further refinement and optimisation and a 200 patient clinical verification study has now completed enrolment.

ANGLE's technology for the multiplex evaluation of proteins and nucleic acids of all types is called the HyCEAD ^TM platform and is based on a patented flow through array technology. It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry approach (the HyCEAD method) allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. The HyCEAD system is extremely sensitive and is ideal for measuring gene expression and other markers directly from Parsortix harvests and was used in the ovarian cancer pelvic mass triage test to achieve best in class accuracy (AUC-ROC) of 95.1%.

ANGLE's proprietary technologies can be combined to provide automated, sample-to-answer results in both centralised laboratory and point-of-use cartridge formats.

ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers. These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 49 peer-reviewed publications and numerous publicly available posters, available on our website.

ANGLE has established clinical services laboratories in the UK and USA to accelerate commercialisation of the Parsortix system and act as demonstrators to support product development. The laboratories offer services to pharmaceutical and biotech customers for use of Parsortix in cancer drug trials and, once the laboratories are accredited and tests validated, will provide Laboratory Developed Tests (LDTs) for patient management.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

ANGLE plc	+44 (0) 1483 343434
Andrew Newland, Chief Executive Ian Griffiths, Finance Director Andrew Holder, Head of Investor Relations
Berenberg (NOMAD and Joint Broker) Toby Flaux, Jen Clarke, Milo Bonser, Shiv Dave	+44 (0) 20 3207 7800
Jefferies (Joint Broker) Max Jones, Thomas Bective	+44 (0) 20 7029 8000
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (United States)	+44 (0) 203 727 1000 +1 (212) 850 5624

SOURCE: ANGLE plc

View source version on accesswire.com:
https://www.accesswire.com/672647/Angle-PLC-Announces-Issue-of-Equity

FAQ

What is the significance of ANGLE plc issuing new ordinary shares on November 12, 2021?

ANGLE plc issued 70,000 new ordinary shares due to employee options exercise, increasing total shares to 235,043,717.

How many total shares will ANGLE plc have after the new issue?

After the new issue, ANGLE plc will have a total of 235,043,717 ordinary shares.

What is the stock symbol for ANGLE plc?

ANGLE plc trades under the stock symbol ANPCY on the OTCQX.

Why is FDA clearance important for ANGLE plc?

FDA clearance is crucial for ANGLE plc as it would validate their Parsortix liquid biopsy system, expanding market potential.

What is the clinical trial success rate for ANGLE's ovarian cancer test?

ANGLE's ovarian cancer pelvic mass triage test achieved a best-in-class accuracy (AUC-ROC) of 95.1%.